A Prospective, Multicenter, Open-label, Single-arm, Phase 2 Study to Investigate the Safety, Tolerability and Pharmacokinetics of Selexipag in Children With Pulmonary Arterial Hypertension
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 07 Aug 2018 Planned primary completion date changed from 30 Sep 2018 to 30 Sep 2020.
- 07 Aug 2018 Status changed from not yet recruiting to recruiting.
- 11 Jul 2018 Planned initiation date changed from 30 Jun 2018 to 30 Jul 2018.